The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by ...
S-OLARIS axSpA Data and PPP Fast Track Unlock Multi-Indication OptionalityCurrent PriceTarget PriceUpsideEntry Price $17.50$29.00+66%$6.24 (9/29/25)RatingCash Key CatalystEntBUY$318MIZAR-1 Q2 2026We ...
With Fast Track designation, we believe this can support the acceleration of our Phase 3 program through earlier and more frequent FDA engagement, enabling faster addressing of development questions, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results